Here's a link from the recent ASTRO meeting regarding the addition of EBRT to brachytherapy.
https://www.medscape.com/viewarticle/adding-ebrt-brachytherapy-did-not-improve-higher-risk-2024a1000hzs
The impression that I got from the Royal Flush presentation by Mira Keyes was that the combination therapy was beneficial in high risk patients in that it shortened the length of time on ADT. But, showed no improvement in overall survival.

The link to her presentation is:

All of this begs the question as to how to approach unfavorable intermediate and high risk patients especially when considering higher Gleason scores, high Decipher scores, etc.

Sure, they come out with this stuff after I've completed brachytherapy, IMRT and am on the last legs of ADT!